S.C.R. 69 Summary

• Department of Health is requested to establish a Beneficial Treatments Advisory Council to review and recommend new medicinal mental health treatments, particularly psilocybin and MDMA which have received FDA breakthrough therapy designation.

• Council is requested to examine federal, state, and local laws regarding medicinal mental health treatments; existing medical and scientific research on safety and efficacy; and requirements for medical professionals to prescribe these treatments.

• Council is requested to develop a long-term strategic plan for safe, accessible, and affordable availability of therapeutic psilocybin, psilocybin-based products, and MDMA for adults ages 21 and older.

• Council membership includes the Executive Director of the Office of Wellness and Resilience (chair), Attorney General, State Council on Mental Health chairperson, physicians with psychiatry and substance abuse specialties, and representatives from psychedelic advocacy and research organizations.

• Council must submit preliminary findings to the Legislature by twenty days before the 2024 Regular Session and final findings with proposed legislation by twenty days before the 2025 Regular Session, then dissolve on July 1, 2025.